Biopharmaceutical Company Selected By BARDA For Novel ARDS Treatment

InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory treatments through targeting the complement system, announced that its investigational drug GOHIBIC (vilobelimab) has been chosen by the Biomedical Advanced Research and Development Authority (BARDA). This selection places vilobelimab among three investigational therapies to be evaluated in a Phase 2 clinical platform study focused on novel treatments for acute respiratory distress syndrome (ARDS). This clinical trial is conducted under the auspices of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. $InflaRx (IFRX.US)$